#USA #New York #Gross Law Firm #class action lawsuit #Soleno Therapeutics

Soleno Therapeutics Shareholder Alert

On April 14, 2026, The Gross Law Firm issued a crucial notification aimed at shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO). This announcement provides key information related to the ongoing securities class action lawsuit involving the company.

Important Details for Shareholders

The law firm encourages shareholders who acquired shares within a specified class period from March 26, 2025, to November 4, 2025, to reach out to them if they are considering applying for the role of lead plaintiff. Notably, participation as a lead plaintiff is not a prerequisite for recovering one’s losses.

Allegations and Concerns

The lawsuit raises serious allegations regarding the company’s previous statements and practices. It is claimed that Soleno, throughout the aforementioned class period, made materially misleading statements. Specifically, the complaint accuses the defendants of:

• - Underreporting Safety Issues: The Phase 3 clinical trial for Soleno’s product, diazoxide choline extended-release tablets (DCCR), allegedly downplayed critical safety evidence linking the drug's administration to issues like excess fluid retention in participants.
• - Misrepresentation of Product Risks: The safety risks associated with DCCR for controlling hyperphagia in individuals with Prader-Willi Syndrome (PWS) were reportedly misrepresented, presenting greater danger than disclosed.
• - Questioning Commercial Viability: Due to the alleged safety concerns, the lawsuit asserts that DCCR has lower commercial viability than what was previously communicated, exacerbated by unaddressed risks tied to patient discontinuation rates and adoption issues, as well as potential regulatory repercussions.

Key Deadlines and Next Steps

Shareholders are urged to act promptly, as the deadline for registering to be considered for lead plaintiff status is set for May 5, 2026. To register, affected shareholders can find the registration form linked in the notice.

Once registered, you will be enrolled in a portfolio monitoring software that will keep you updated on case developments throughout its lifecycle. Importantly, there are no costs or obligations associated with joining the case.

Why Choose Gross Law Firm?

The Gross Law Firm is a respected name in class action law, focused on safeguarding the rights of investors impacted by fraud and deceptive business practices. Their dedication lies in ensuring that companies operate responsibly and transparently. The team advocates for investors who have faced losses due to misleading statements that artificially inflated stock values.

Contact Information

For shareholders looking to seek clarity on their position or interested in participating in the class action, they can reach out directly to The Gross Law Firm:

• - Address: 15 West 38th Street, 12th Floor, New York, NY 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

Stay informed and safeguard your investments by staying engaged with these legal proceedings and understand your rights as a shareholder during this critical time in Soleno Therapeutics’ journey.